Trial intelligence / Profile preview

Safety and Immunogenicity of 202-CoV Vaccine in Adults for COVID-19 Prevention

NCT04990544Phase 2Unknown

Sponsor
Shanghai Zerun Biotechnology Co., Ltd.
Start
Jul 2021
Primary completion
Apr 2022
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

A Phase 2 trial of ZR202-CoV in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Status: unknown.

02

Drugs

ZR202-CoV
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT04990544.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04990544.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call